GlycoNex announced a collaborative research agreement with Hokkaido University Hospital to support the development of its next-generation antibody-drug conjugate (ADC) GNX1021 in gastric cancer

CAR-T Digest - August 2020

Weekly Digest - November 2025

20 November 2025: GlycoNex announced a collaborative research agreement with Hokkaido University Hospital to support the development of its next-generation antibody-drug conjugate (ADC) GNX1021 in gastric cancer

GlycoNex entered a collaborative research agreement with Hokkaido University Hospital to support the development of its next-generation ADC, GNX1021, for gastric cancer and prepare for future clinical trials in Japan
The collaboration includes a retrospective study to evaluate the expression of the bLeB/Y glycan antigen in Japanese gastric cancer patients and its relationship with established biomarkers such as HER2, CLDN18, PD-L1, and MMR
Gastric cancer remains a major health burden in Japan, with over 115,000 new cases and nearly 40,000 deaths projected in 2024, underscoring the need for new treatment approaches
Insights from the biomarker analysis aim to define the patient population most likely to benefit from GNX1021, improving its potential for clinical success
GNX1021 has shown strong preclinical activity, including in models resistant to HER2- and CLDN18-targeted therapies, and is progressing toward regulatory submissions, with Phase I trials planned for 2026